Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab

Maurizio Battaglia Parodi, Umberto De Benedetto, Karl Anders Knutsson, Fabrizio Scotti, Aloisa Librando, Francesco Bandello, Pierluigi Iacono

Research output: Contribution to journalArticle

Abstract

Purpose: To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. Methods: A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. Results: At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Conclusions: Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.

Original languageEnglish
Pages (from-to)202-204
Number of pages3
JournalJournal of Ocular Pharmacology and Therapeutics
Volume28
Issue number2
DOIs
Publication statusPublished - Apr 1 2012

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Fingerprint Dive into the research topics of 'Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab'. Together they form a unique fingerprint.

  • Cite this